These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

519 related items for PubMed ID: 17548745

  • 1. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW.
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract] [Full Text] [Related]

  • 2. Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998 Jun; 59 Suppl 12():35-40. PubMed ID: 9766618
    [Abstract] [Full Text] [Related]

  • 3. The effects of clozapine on cognitive functioning in schizophrenia.
    McGurk SR.
    J Clin Psychiatry; 1999 Jun; 60 Suppl 12():24-9. PubMed ID: 10372607
    [Abstract] [Full Text] [Related]

  • 4. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.
    Velligan DI, Miller AL.
    J Clin Psychiatry; 1999 Jun; 60 Suppl 23():25-8. PubMed ID: 10625197
    [Abstract] [Full Text] [Related]

  • 5. Treatment of cognitive dysfunction in schizophrenia.
    Peuskens J, Demily C, Thibaut F.
    Clin Ther; 2005 Jun; 27 Suppl A():S25-37. PubMed ID: 16198199
    [Abstract] [Full Text] [Related]

  • 6. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA, CATIE Investigators, Neurocognitive Working Group.
    Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746
    [Abstract] [Full Text] [Related]

  • 7. Effects of clozapine on cognitive function in schizophrenia.
    Lee MA, Thompson PA, Meltzer HY.
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():82-7. PubMed ID: 7961582
    [Abstract] [Full Text] [Related]

  • 8. Neurocognitive deterioration in elderly chronic schizophrenia patients with and without PTSD.
    Goodman C, Finkel B, Naser M, Andreyev P, Segev Y, Kurs R, Melamed Y, Bleich A.
    J Nerv Ment Dis; 2007 May; 195(5):415-20. PubMed ID: 17502807
    [Abstract] [Full Text] [Related]

  • 9. Spatial working memory and problem solving in schizophrenia: the effect of symptom stabilization with atypical antipsychotic medication.
    Snyder PJ, Jackson CE, Piskulic D, Olver J, Norman T, Maruff P.
    Psychiatry Res; 2008 Sep 30; 160(3):316-26. PubMed ID: 18579217
    [Abstract] [Full Text] [Related]

  • 10. Cognitive effects of conventional and atypical antipsychotics in schizophrenia.
    Sharma T.
    Br J Psychiatry Suppl; 1999 Sep 30; (38):44-51. PubMed ID: 10884899
    [No Abstract] [Full Text] [Related]

  • 11. Important steps in the development of cognitive-enhancing drugs in schizophrenia.
    Buchanan RW.
    Am J Psychiatry; 2006 Nov 30; 163(11):1867-9. PubMed ID: 17074932
    [No Abstract] [Full Text] [Related]

  • 12. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
    Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R.
    Arch Gen Psychiatry; 2006 Jun 30; 63(6):630-8. PubMed ID: 16754836
    [Abstract] [Full Text] [Related]

  • 13. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
    Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, Woerner MG, Schooler NR, Kane JM, Robinson DG.
    Arch Gen Psychiatry; 2007 Oct 30; 64(10):1115-22. PubMed ID: 17909123
    [Abstract] [Full Text] [Related]

  • 14. Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions.
    Green MF.
    Am J Psychiatry; 2007 Jul 30; 164(7):992-4. PubMed ID: 17606645
    [No Abstract] [Full Text] [Related]

  • 15. Atypical antipsychotic drugs improve cognition in schizophrenia.
    Meltzer HY, Sumiyoshi T.
    Biol Psychiatry; 2003 Feb 01; 53(3):265-7; author reply 267-8. PubMed ID: 12559661
    [No Abstract] [Full Text] [Related]

  • 16. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A, Ritsner MS.
    Clin Neuropharmacol; 2008 Feb 01; 31(4):204-20. PubMed ID: 18670244
    [Abstract] [Full Text] [Related]

  • 17. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.
    Keefe RS, Silva SG, Perkins DO, Lieberman JA.
    Schizophr Bull; 1999 Feb 01; 25(2):201-22. PubMed ID: 10416727
    [Abstract] [Full Text] [Related]

  • 18. Cognitive neuroscience and schizophrenia: translational research in need of a translator.
    Cohen JD, Insel TR.
    Biol Psychiatry; 2008 Jul 01; 64(1):2-3. PubMed ID: 18549873
    [No Abstract] [Full Text] [Related]

  • 19. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC, Navarre M, Eskenazi AM, Lucas-Ross M, Falissard B.
    Encephale; 2008 Dec 01; 34(6):557-62. PubMed ID: 19081451
    [Abstract] [Full Text] [Related]

  • 20. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.
    Harvey PD, Keefe RS.
    Am J Psychiatry; 2001 Feb 01; 158(2):176-84. PubMed ID: 11156796
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.